Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.71 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.71 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | IL1B | P01584 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20317524 | 0.92 | CRBN (0.61) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL17246852 | 0.86 | CRBN (0.77) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL677366 | 0.86 | CRBN (0.77) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL12408666 | 0.86 | CRBN (0.57) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL23707575 | 0.85 | DDB1 (0.77) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL16186482 | 0.85 | CRBN (0.77) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL2615525 | 0.84 | CRBN (0.76) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL2615524 | 0.84 | CRBN (0.76) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL17277068 | 0.84 | CRBN (0.76) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| Thalidomide SCHEMBL411175 | 0.83 | CRBN (1.00) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20130136757-A1 | METHODS OF TREATING CANCER USING A COMBINATION OF AN IMMUNOMODULATORY COMPOUND AND AN ARTEMISININ OR A DERIVATIVE THEREOF | ST. GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) | 2013-05-30 | — | — | US | disclosed |
| US-20120190110-A1 | IMMUNOLOGICAL USES OF IMMUNOMODULATORY COMPOUNDS FOR VACCINE AND ANTI-INFECTIOUS DISEASE THERAPY | BARTLETT JUSTIN B (US) | 2012-07-26 | — | — | US | disclosed |
| US-8216571-B2 | Fully human anti-VEGF antibodies and methods of using | SCHERING CORPORATION (US) | 2012-07-10 | — | — | US | disclosed |
| US-20120064004-A1 | ISOTOPOLOGUES OF THALIDOMIDE | CELGENE CORPORATION | 2012-03-15 | — | — | US | disclosed |
| US-20120035068-A1 | USE OF MIRCO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY | CELGENE CORPORATION | 2012-02-09 | — | — | US | disclosed |
| US-20110318401-A1 | TREATMENT OF LEG ULCERS USING PLACENTA DERIVED COLLAGEN BIOFABRIC | CELULARITY INC. | 2011-12-29 | — | — | US | disclosed |
| US-20110280849-A1 | TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATORY COMPOUNDS | ANTHROGENESIS CORPORATION (US) | 2011-11-17 | — | — | US | disclosed |
| US-8012996-B2 | Methods and composition for inhibition of angiogenesis | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | CRBN 1640/4885DDB1 1788/4885IKZF3 3249/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | CRBN 1199/4885DDB1 511/4885IKZF3 578/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CRBN 3/4885DDB1 433/4885IKZF3 3470/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | CRBN 438/4885DDB1 611/4885IKZF3 1418/4885 |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CRBN 3/4885DDB1 750/4885IKZF3 3015/4885 |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885IKZF3 354/4885 |
| US-20110280849-A1 | TUMOR SUPPRESSION USING HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS AND IMMUNOMODULATORY COMPOUNDS | PGF, PBK, NFATC1 | CRBN 969/4885DDB1 2050/4885IKZF3 13/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | CRBN 195/4885DDB1 567/4885IKZF3 821/4885 |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | CRBN 439/4885DDB1 507/4885IKZF3 251/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | CRBN 163/4885DDB1 576/4885IKZF3 1199/4885 |
| US-20120064004-A1 | ISOTOPOLOGUES OF THALIDOMIDE | CDK4, FKBP8, FKBP1A | CRBN 475/4885DDB1 1013/4885IKZF3 754/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | CRBN 679/4885DDB1 175/4885IKZF3 606/4885 |
| US-20130136757-A1 | METHODS OF TREATING CANCER USING A COMBINATION OF AN IMMUNOMODULATORY COMPOUND AND AN ARTEMISININ OR A DERIVATIVE THEREOF | CD47, IL2, MCL1 | CRBN 1086/4885DDB1 944/4885IKZF3 42/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | CRBN 438/4885DDB1 611/4885IKZF3 1418/4885 |
| US-20110318401-A1 | TREATMENT OF LEG ULCERS USING PLACENTA DERIVED COLLAGEN BIOFABRIC | PGF, COL14A1, COL1A1 | CRBN 663/4885DDB1 619/4885IKZF3 1970/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CRBN 74/4885DDB1 706/4885IKZF3 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.